20080305.TNBC
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.730
- INTERFERON_GAMMA_RESPONSE+0.690
- ALLOGRAFT_REJECTION+0.650
- IL6_JAK_STAT3_SIGNALING+0.550
- INFLAMMATORY_RESPONSE+0.490
- COMPLEMENT+0.410
- E2F_TARGETS+0.370
- IL2_STAT5_SIGNALING+0.330
- KRAS_SIGNALING_UP+0.270
- G2M_CHECKPOINT+0.260
Top 10 suppressed
- UV_RESPONSE_DN-0.370
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.360
- ANGIOGENESIS-0.280
- ESTROGEN_RESPONSE_EARLY-0.260
- TGF_BETA_SIGNALING-0.200
- APICAL_JUNCTION-0.170
- CHOLESTEROL_HOMEOSTASIS-0.170
- ANDROGEN_RESPONSE-0.150
- MYOGENESIS-0.140
- HEDGEHOG_SIGNALING-0.130
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 20030081.TNBC | — | D | 0.916 |
| 2 | TCGA-C8-A12K-01A-21R-A115-07 | — | E | 0.896 |
| 3 | SRR8518188 | — | D | 0.881 |
| 4 | BSR_16_0031_E2_S98 | — | C | 0.879 |
| 5 | TCGA-EW-A1PB-01A-11R-A144-07 | — | E | 0.870 |
| 6 | TCGA-AO-A128-01A-11R-A10J-07 | — | D | 0.863 |
| 7 | TCGA-AR-A1AQ-01A-11R-A12P-07 | — | E | 0.862 |
| 8 | SRR8518156 | — | D | 0.858 |
| 9 | TCGA-E9-A22D-01A-11R-A157-07 | — | D | 0.854 |
| 10 | TCGA-AR-A0U0-01A-11R-A109-07 | — | E | 0.854 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.730 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.690 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.650 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.550 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.490 | Idelalisib | — uncovered |
| COMPLEMENT | 0.410 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.370 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.330 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.270 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.260 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.250 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.240 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.240 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.230 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.200 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.190 | Inavolisib | — uncovered |
| APOPTOSIS | 0.180 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.170 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.160 | Temsirolimus | — uncovered |
| APICAL_SURFACE | 0.150 | Temsirolimus | — uncovered |